It is well known that the increase in TGF‐β and IL‐10 in the TME is an inevitable consequence of cancer vaccine immunotherapy, and anti‐inflammatory cytokines are among the main obstacles that reduce anti‐tumor immunity by promoting immune‐suppressive environments.[42, 47, 48] Therefore, the fact that supra‐adjuvants showed an ability to reduce the increased anti‐inflammatory cytokines is significant. This evidence concerns the gene TGFB1 and neoplasm.